vTv Therapeutics (VTVT) Stock Forecast & Price Target

Compare

788 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

VTVT Analyst Ratings

Strong Buy

4 Buy

0 Hold

0 Sell

Based on 4 analysts giving stock ratings to

vTv

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

VTVT Stock 12 Month Forecast

Average Price Target

$55.25

▲(43.43% Upside)

Based on 4 Wall Street analysts offering 12 month price targets for vTv Therapeutics in the last 3 months. The average price target is $55.25 with a high forecast of $67.00 and a low forecast of $47.00. The average price target represents a 43.43% change from the last price of $38.52.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"12":"$12","26":"$26","40":"$40","54":"$54","68":"$68"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":67,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$67.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":55.25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$55.25</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":47,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$47.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[12,26,40,54,68],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"May<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,38.31,40.51692307692308,42.723846153846154,44.93076923076923,47.137692307692305,49.34461538461538,51.55153846153846,53.75846153846154,55.965384615384615,58.17230769230769,60.379230769230766,62.58615384615385,64.79307692307692,{"y":67,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,38.31,39.613076923076925,40.91615384615385,42.21923076923077,43.52230769230769,44.825384615384614,46.128461538461536,47.431538461538466,48.73461538461538,50.03769230769231,51.340769230769226,52.643846153846155,53.94692307692308,{"y":55.25,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,38.31,38.97846153846154,39.64692307692308,40.315384615384616,40.98384615384616,41.652307692307694,42.32076923076923,42.98923076923077,43.65769230769231,44.326153846153844,44.994615384615386,45.66307692307692,46.331538461538464,{"y":47,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":14.26,"date":1677628800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.03,"date":1730419200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":15.63,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":13.81,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":19.66,"date":1740787200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":16.4,"date":1743465600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":20.51,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.58,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.4,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.75,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.5,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.99,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.31,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 31, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$67.00

Average Price Target$55.25

Lowest Price Target$47.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Emily Bodnar

H.C. Wainwright

$47

Buy

22.01%

Upside

Reiterated

02/02/26

Analysts Are Bullish on Top Healthcare Stocks: Pelthos Therapeutics (PTHS), Twist Bioscience (TWST)

Kambiz Yazdi

BTIG

$49

Buy

27.21%

Upside

Reiterated

02/02/26

Analysts Are Bullish on These Healthcare Stocks: vTv Therapeutics (VTVT), Acumen Pharmaceuticals (ABOS)

Adam Walsh

Roth MKM

$58

Buy

50.57%

Upside

Initiated

01/25/26

Analysts' Top Healthcare Picks: OKYO Pharma Limited Sponsored ADR (OKYO), vTv Therapeutics (VTVT)

Ritu Baral

TD Cowen

$67

Buy

73.94%

Upside

Initiated

01/05/26

Paradigm-Shifting Potential in Type 1 Diabetes: vTv Therapeutics’ Cadisegliatin Supports Buy Rating and Significant Upside

James Molloy

Alliance Global Partners

$35

Buy

-9.14%

Downside

Reiterated

05/16/25

Analysts Offer Insights on Healthcare Companies: vTv Therapeutics (NASDAQ: VTVT) and Precision BioSciences (NASDAQ: DTIL)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Emily Bodnar

H.C. Wainwright

$47

Buy

22.01%

Upside

Reiterated

02/02/26

Analysts Are Bullish on Top Healthcare Stocks: Pelthos Therapeutics (PTHS), Twist Bioscience (TWST)

Kambiz Yazdi

BTIG

$49

Buy

27.21%

Upside

Reiterated

02/02/26

Analysts Are Bullish on These Healthcare Stocks: vTv Therapeutics (VTVT), Acumen Pharmaceuticals (ABOS)

Adam Walsh

Roth MKM

$58

Buy

50.57%

Upside

Initiated

01/25/26

Analysts' Top Healthcare Picks: OKYO Pharma Limited Sponsored ADR (OKYO), vTv Therapeutics (VTVT)

Ritu Baral

TD Cowen

$67

Buy

73.94%

Upside

Initiated

01/05/26

Paradigm-Shifting Potential in Type 1 Diabetes: vTv Therapeutics’ Cadisegliatin Supports Buy Rating and Significant Upside

James Molloy

Alliance Global Partners

$35

Buy

-9.14%

Downside

Reiterated

05/16/25

Analysts Offer Insights on Healthcare Companies: vTv Therapeutics (NASDAQ: VTVT) and Precision BioSciences (NASDAQ: DTIL)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering vTv Therapeutics

3 Months

xxx

Success Rate

4/7 ratings generated profit

Average Return

+23.16%

reiterated a xxx

rating 25 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 57.14% of your transactions generating a profit, with an average return of +23.16% per trade.

1 Year

James MolloyAlliance Global Partners

Not Ranked

Success Rate

3/3 ratings generated profit

Average Return

+68.40%

reiterated a buy rating 10 months ago

Copying James Molloy's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +68.40% per trade.

2 Years

xxx

Success Rate

3/3 ratings generated profit

Average Return

+73.83%

reiterated a xxx

rating 10 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +73.83% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

VTVT Analyst Recommendation Trends

Rating

Sep 25

Nov 25

Dec 25

Jan 26

Feb 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, VTVT has received 7 Buy Ratings, 31 Hold Ratings, and 4 Sell Ratings. VTVT average Analyst price target in the past 3 months is 55.25.

Each month's total comprises the sum of three months' worth of ratings.

VTVT Financial Forecast

VTVT Earnings Forecast

Currently, no earnings data available.

VTVT Sales Forecast

Currently, no sales data available.

VTVT Stock Forecast FAQ

What is VTVT’s average 12-month price target, according to analysts?

Based on analyst ratings, vTv Therapeutics’s 12-month average price target is 55.25.

What is VTVT’s upside potential, based on the analysts’ average price target?

vTv Therapeutics has 43.43% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is VTVT a Buy, Sell or Hold?

vTv Therapeutics has a consensus rating of Strong Buy which is based on 4 buy ratings, 0 hold ratings and 0 sell ratings.

What is vTv Therapeutics’s price target?

The average price target for vTv Therapeutics is 55.25. This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $67.00 ,the lowest forecast is $47.00. The average price target represents 43.43% Increase from the current price of $38.52.

What do analysts say about vTv Therapeutics?

vTv Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 4 Wall Streets Analysts.

How can I buy shares of VTVT?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

vTv Therapeutics (VTVT) Stock Forecast & Price Target

VTVT Analyst Ratings

VTVT Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering vTv Therapeutics

VTVT Analyst Recommendation Trends

VTVT Financial Forecast

VTVT Earnings Forecast

VTVT Sales Forecast

VTVT Stock Forecast FAQ

Detailed List of Analyst Forecasts